| Biotech Innovators,
It’s been a little over a year since I joined Absci as Chief Innovation Officer after many years in Big Pharma. In that time, I’ve only grown more impressed at the ability of AI to create novel biologics. In the last few months alone: We announced our collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. We announced our drug discovery partnership with Almirall to develop novel treatments for dermatological diseases. We revealed our rapidly developed internal drug discovery pipeline, including ABS-101, a potential best-in-class TL1A candidate, created with two of our AI technologies: de novo design and multiparameter lead optimization. We published a new manuscript about IgDesign™, a novel antibody inverse folding model. These are exciting developments, and we’re just as excited about the continued evolution of our platform.
Meet us at the JP Morgan Healthcare Conference on January 8-11 in San Francisco to learn more, or drop us a note if you’re interested in becoming a part of our Drug Creation™ journey.
Kind regards,
Andreas Busch, Ph.D.
Absci Chief Innovation Officer |
